Q-omics provides the consensus-scored RBMXP1 profile across patient tissues and cancer cell-line models. RBMXP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RBMXP1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RBMXP1 RNA expression shows 5,807 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, HNSC, and STAD as cancer lineages where RBMXP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMXP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMXP1 survival associations across molecular data types. RBMXP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMXP1 RNA expression–survival associations across cancer types. High RBMXP1 expression shows unfavorable associations in BLCA, STAD, THCA, OV and MESO, but favorable associations in READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RBMXP1 RNA expression.
This table summarizes RBMXP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RBMXP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMXP1 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, COAD, LUSC and BRCA. The HNSC box plot shows higher RBMXP1 RNA expression in tumor versus normal tissue (log2 FC = +0.104, t-test p < 0.001).
This table shows molecular features associated with RBMXP1 in patient tissues and cancer cell lines. In patient samples, RBMXP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
